Document is current
Any future updates will be listed below
-
Authors
Cuesta-Marti, Cristina
Valderrama, Benjamin
Bastiaanssen, Thomaz
Cryan, John F.
Stanton, Catherine
O’Mahony, Siobhain M.
Clarke, Gerard
Schellekens, Harriët
-
Funding
Funding for this research was provided by:
Irish Research Council (GOIPG/2023/4836)
Science Foundation Ireland (SFI/12/RC/2273_P2, SFI/12/RC/2273_P2, SFI/12/RC/2273_P2, SFI/12/RC/2273_P2, SFI/12/RC/2273_P2, SFI/12/RC/2273_P2, SFI/12/RC/2273_P2, SFI/12/RC/2273_P2)
- License Information
-
More Information
Article History
Received: 30 January 2025
Accepted: 25 August 2025
First Online: 3 October 2025
Competing interests
: The authors declare no competing non-financial interests but the following competing financial interests. G.C. has received honoraria as an invited speaker from Janssen, Probi, Boehringer Ingelheim, and Aspen, and has obtained research funding from Pharmavite, Reckitt, Tate & Lyle PLC, Nestlé, and Fonterra. Additionally, G.C. serves or has served as a paid consultant for Heel Pharmaceuticals, Bayer Healthcare, Yakult, and Zentiva. H.S. received funding from the Geneva BIOSTIME Institute Nutrition and Care (BINC) Foundation and Food for Health Ireland through the EI Technology Centre award (TC20180025). H.S. has obtained research funding from Pharmavite, Cremo, Tate & Lyle PLC, Pepsico, and Fonterra. The funding sources did not influence or constrain the study design, collection, analysis, data interpretation, or writing of the manuscript. H.S., J.F.C., and C.S. are inventors on a patent for other findings previously identified with the in-house bacterial strain used in the present work (filed and pending, EP17187989.3, entitled: “Bifidobacterium longum APC1472 for treating obesity and weight management”).
